S3V Vascular Technologies Limited
S3V Vascular Technologies Limited
INE0HGT01012
Incorporation Date: 09-Aug-2011
Listing Status: DRHP Not Filed
About S3V Vascular Technologies Limited
Overview of S3V Vascular Technologies Limited
Company Overview
S3V Vascular Technologies Limited is an Indian medical device company focused on advanced vascular, neurovascular, and spinal intervention solutions. The company is built around a single mission: making complex, life-saving interventional procedures affordable and widely accessible, particularly in emerging healthcare markets like India.S3V primarily operates on a B2B model, partnering with hospitals, clinicians, and public healthcare systems to enable large-scale adoption of minimally invasive therapies.

Core Focus Areas
S3V specializes in high-precision interventional technologies across three critical segments:
Neurovascular intervention (stroke and brain clot removal)
Vascular intervention (stents and catheters)
Spine and orthopaedic implants
A key differentiator is its focus on cost-efficient innovation, delivering clinically effective alternatives to expensive imported devices while maintaining global quality standards.

Breakthrough in Stroke Care
S3V is a pioneer in affordable brain clot removal solutions. Its indigenously developed neuro-intervention devices have reduced the cost of stroke treatment from ₹9–10 lakh to nearly ₹1 lakh, dramatically improving access to timely stroke care.
The company is developing a complete brain clot removal (neuro thrombectomy) kit, targeted for commercial availability from Q4 FY26, positioning S3V as a key enabler in India’s stroke-care ecosystem.
![]()
Product Portfolio
S3V has built a diversified, innovation-led product portfolio spanning neuro, vascular, and spine applications:
3V Vajra – Expandable titanium-based spinal cage
3V Agile – Oesophageal stents
3V Astra – Aspiration catheter
3V Neil – Biodegradable drug-eluting stents
3V Paulo – Balloon dilatation catheter
Neuro Kit – Integrated brain clot removal system (upcoming)
Notably, S3V is the first company globally licensed for an expandable titanium-based intervertebral body fusion cage, underlining its strong R&D depth.

Manufacturing & Regulatory Strength
In May 2025, S3V received CDSCO approval to manufacture Class C and Class D medical devices across neuro and spine categories — among the most stringently regulated segments in med-tech.
This approval strengthens S3V’s domestic manufacturing credibility, ensures regulatory compliance at global standards, and enables future international expansion.
Business Model & Market Strategy
S3V follows a hospital-led B2B commercialization strategy, working closely with:
Multi-specialty and tertiary care hospitals
Neuro, vascular, and spine surgeons
Government healthcare programs such as PMJAY (Ayushman Bharat)
This approach enables high-volume institutional adoption, price stability, and predictable long-term demand.
Why S3V Matters
S3V Vascular Technologies sits at the intersection of deep-tech innovation and affordable healthcare delivery. With strong regulatory approvals, first-of-its-kind products, and a clear cost-disruption strategy, the company is emerging as a strategic force in India’s medical device self-reliance journey, with products that are also globally relevant.
Insights of S3V Vascular Technologies Limited
Financial Charts of S3V Vascular Technologies Limited
Balance Sheet of S3V Vascular Technologies Limited
Profit and Loss of S3V Vascular Technologies Limited
Ancillary of S3V Vascular Technologies Limited
Ratio Analysis
Peers
Industry Benchmarking
Segment Revenue
Subsidaries
Security Allotment
Corporate Governance
Team Management Details
FAQs of S3V Vascular Technologies Limited
-
How to buy S3V Vascular Technologies Limited?
Below are three ways through which you can purchase S3V Vascular Technologies Limited:
- We at Altius Investech have many actively traded scripts and are market makers of unlisted shares. To check out all the unlisted shares traded. (Click on link). To submit a request to buy S3V Vascular Technologies Limited, please click on the trade button at the top of this page
- Additionally, you can download our app from your play store or app store, register on our application, and engage in active trading there.
Download the Altius App here https://onelink.to/hf4m72 - You can also reach out to us at : +91 8240614850 / +91 8240861716
-
How to sell S3V Vascular Technologies Limited?
Below are three ways through which you can sell S3V Vascular Technologies Limited:
- We at Altius Investech have many actively traded scripts and are market makers of unlisted shares. To check out all the unlisted shares traded. (Click on link). To submit a request to sell S3V Vascular Technologies Limited, please click on the trade button at the top of this page
- Additionally, you can download our app from your play store or app store, register on our application, and engage in active trading there.
Download the Altius App here https://onelink.to/hf4m72 - You can also reach out to us at : +91 8240614850 / +91 8240861716
-
What is the price of S3V Vascular Technologies Limited?
We provide a two way quote on all the shares we deal in. Your buy price for S3V Vascular Technologies Limited is ₹399 and your sell price for S3V Vascular Technologies Limited is ₹333. The price is based on our estimates and market conditions.
-
What is the lock-in period of S3V Vascular Technologies Limited?
The lock-in period for S3V Vascular Technologies Limited varies depending on the category of investors:
- For retail Investors, HNIs, or Body Corporates, the lock-in period is 6 months from the date of the listing of S3V Vascular Technologies Limited
- For Venture Capital Funds or Foreign Venture Capital Investors, there is a lock-in period of 6 months from the date of acquisition of S3V Vascular Technologies Limited
- For AIF-II (Alternative Investment Funds - Category II), there is no lock-in period
August 2021 saw the introduction of this regulation by SEBI. The purpose of the regulation change, which lowered the lock-in period from a year to six months, was to incentivize additional investments in firms getting ready for initial public offerings, or IPOs. Since its introduction, a number of Portfolio Management Services (PMS) have advised their clients to purchase Pre-IPO shares in order to take advantage of the advantages associated with early-stage investments. This reduction in the lock-in period is considered as a significant step forward.
-
How is the S3V Vascular Technologies Limited price calculated?
Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of S3V Vascular Technologies Limited. The price is also determined from the most recent funding round for S3V Vascular Technologies Limited. This provides us with a benchmark valuation, offering a clear indication of the company's current market value as perceived by investors and industry experts.
-
What are the lot sizes of S3V Vascular Technologies Limited?
We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of S3V Vascular Technologies Limited with us kindly click here.
-
What are the financials of S3V Vascular Technologies Limited?
The financials of S3V Vascular Technologies Limited which includes the P/L of S3V Vascular Technologies Limited and the Balance Sheet of S3V Vascular Technologies Limited is in the financials section (Click on link).
-
Where can I find the annual report of S3V Vascular Technologies Limited?
The annual report of S3V Vascular Technologies Limited is available in the annual report section (Click on link).
-
Is buying S3V Vascular Technologies Limited legal in India?
Yes, buying and selling unlisted shares in India is indeed 100% legal. This activity is regulated and governed under the guidelines provided by the Securities and Exchange Board of India (SEBI). Investors and traders must adhere to these regulations and guidelines to ensure compliance with legal and financial standards. It's important for participants in the unlisted share market to be aware of and understand these regulations to engage in transactions legally and securely.
-
Short-term Capital Gain taxes to be paid on S3V Vascular Technologies Limited?
When you sell unlisted shares within a period of two years from the date of acquisition, any profit earned from the sale is classified as Short-term Capital Gain (STCG). This gain is then added to your total income for that financial year. The tax on this short-term capital gain is calculated based on your applicable individual income tax slab rates. Therefore, the rate at which you will pay tax on the STCG from unlisted shares depends on your total income, including this gain, and the tax slab it falls under as per the prevailing income tax laws in India. It's important for investors to consider these tax implications when engaging in transactions involving unlisted shares.
-
Long-term Capital Gain taxes to be paid on S3V Vascular Technologies Limited and how are They Taxed?
Long-term Capital Gains (LTCG) on unlisted shares in India refer to the profits earned from the sale of unlisted shares that have been held for more than two years. The key aspects of LTCG on unlisted shares include:
- Tax Rate: LTCG on unlisted shares is taxed at a rate of 20%.
- Indexation Benefit: This is a significant advantage for investors. Indexation allows for adjusting the purchase price of the shares for inflation, which can reduce the taxable gain.
- Importance for Investors: Understanding LTCG is crucial, especially for High Net-worth Individuals (HNIs) and retail investors, as it impacts their investment strategy and tax planning. Knowing these details helps in making informed investment decisions.
- Calculation: LTCG is calculated by subtracting the indexed cost of acquisition (the purchase price adjusted for inflation) from the sale price of the shares. The profit thus calculated is subject to a 20% tax.
- Applicability: LTCG tax is applicable to profits from the sale of unlisted shares held for more than two years.
- Relevance: This tax is particularly relevant to investors in the unlisted share market, including those considering selling their holdings after a period of more than two years.
-
Applicability of Taxes on S3V Vascular Technologies Limited once it is listed?
When shares initially bought in the unlisted market become listed, the taxation rules change significantly if these shares are sold through a stock exchange. Here's what investors need to know:
Transition to Listed Market Tax Rates: Once unlisted shares are listed on the stock exchange and subsequently sold, the tax rates applicable to listed securities come into effect. This shift means that the favourable tax treatments for listed shares, as per the prevailing tax laws, will apply.
Taxation Based on Holding Period: The crucial factor in determining the type of capital gains tax (Long-term or Short-term) is the holding period of the shares. Importantly, this period is calculated from the original purchase date when the shares were unlisted.
Long-term vs. Short-term Capital Gains: If the shares are sold after being held for more than one year from the date of purchase (including the period when they were unlisted), they are subject to Long-term Capital Gains (LTCG) tax.
Conversely, if sold within one-year, Short-term Capital Gains (STCG) tax rates apply.
Significance for Investors: This information is vital for investors in the unlisted market, as it impacts their tax planning and decision-making process. Understanding these nuances ensures that investors can strategically plan the sale of their shares post-listing to optimize tax implications.
Advice for Investors: It's advisable for investors to keep a record of their purchase dates and monitor the listing dates closely. Additionally, staying updated with the latest tax regulations or consulting with a financial advisor is recommended for accurate tax calculations and compliance. -
How does Altius Investech source S3V Vascular Technologies Limited?
At Altius Investech, our approach to sourcing Boat Unlisted Share (Imagine Marketing) involves a strategic and direct method. Primarily, we acquire these shares from the below key groups:
Employees of the Company: Employee stock option plans (ESOPs) or other compensation packages frequently include shares for firm employees. For a various reasons, such as including portfolio diversification or financial considerations, some of these employees may eventually choose to sell their shares. We engage with these employees, providing them a platform to sell their shares.
Initial Investors: These are the angel or early-stage investors who provided capital to the business in its early stages. These original investors may look to sell all or part of their ownership position in the company as it develops and flourishes. This might be done for various reasons such as in order to maximise their investment, reallocate resources, or make other calculated financial decisions.
Funding rounds and VC funds: Altius Investech sources the shares from private placement rounds in which private companies seek to obtain capital from the market. Through our platform, venture capital funds can liquidate their shares and we receive the inventory from them when they decide to sell a portion of their ownership through block trades.
By establishing connections with these groups, Altius Investech guarantees our clients a steady and dependable supply of Boat Unlisted Share (Imagine Marketing). This process not only makes it easier for employees and initial investors in liquidating their assets, but it also gives our clients access to shares that aren't often found on the open market. Our platform effectively facilitates a win-win situation for both buyers and sellers. -
How to trust Altius Investech before buying S3V Vascular Technologies Limited from its platform?
Altius Investech stands at being India's fastest growing and leading marketplace for buying and selling unlisted shares. We believe in enabling access to alternative sources of investments at lower entry barriers to private equity investments.
With more than 25 years of experience, Altius Investech has carved a niche in the financial market by serving more than 8000 clients. The incredible journey is further highlighted by the vast number of transactions that Altius Investech has facilitated transactions that have already exceeded 300 crores.
For investors Altius Investech curates investment opportunities in companies at reasonable valuations which are on the verge of an IPO leading to massive value unlocking. Investments are backed by thorough research and sound investment thesis, with a time bound exit plan.
For ESOP Shareholder and existing Investors, we assist them to liquidate their shares even if they are not publicly traded by creating a platform where we find the right buyers and sellers for the best prices.
Altius Investech have been featured in top media news outlets like Economic Times, Financial Express, Money control. Check out about us on these - leading publications (Click on link) Our journey over these years has not just been about numbers; it's been about building trust and reliability.
We at Altius Investech are dedicated to upholding the greatest levels of ethics and transparency, making sure that your investment experience is not only profitable but also safe and reliable.
Press of S3V Vascular Technologies Limited
Featured Blogs of S3V Vascular Technologies Limited
Annual Report of S3V Vascular Technologies Limited
Company Information of S3V Vascular Technologies Limited
Featured Companies


